(Q36736708)

English

Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis

scientific article published on 16 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

0 references

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Tracy McGowan

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Nicole M Vaccaro

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jessica S Beaver

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Joseph Massarella

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Marsha Wolfson

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

16 April 2008

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Clinical Journal of the American Society of Nephrology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1006-1014

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

29 September 2017

Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

29 September 2017

Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

29 September 2017

The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

29 September 2017

Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

28 June 2018

Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

5 September 2018

Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

5 September 2018

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

5 September 2018

Once-weekly epoetin alfa for treating the anemia of chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

5 September 2018

Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440285

5 September 2018

Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18417741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18417741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/18417741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2215/CJN.05671207

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36736708&oldid=2143937299"